Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial
Nicole Basset‐Séguin(Inserm), Johan Hansson(Karolinska University Hospital), Axel Hauschild(Kiel University), Lisa Licitra(University of Milan), Thomas Jouary(Hôpital Saint-André), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Kate Fife(Addenbrooke's Hospital), Jean‐Jacques Grob, B. Guillot(Université de Montpellier), Nicolás Meyer(Université Toulouse III - Paul Sabatier), D. Scott Ernst, Laurent Mortier, L. Thomas, Rainer Kunstfeld(Vienna General Hospital), Reinhard Dummer(University of Zurich), Sarah Williams(Ruhrlandklinik), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Brigitte Dréno(Inserm), Ioannis Xynos(Roche (United Kingdom)), A. Fittipaldo(Roche (United Kingdom))
Cited by 244
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k